您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > Diosmetin
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Diosmetin
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Diosmetin图片
CAS NO:520-34-3
规格:≥98%
包装与价格：
包装价格(元)
100mg电议
250mg电议
500mg电议
1g电议
2g电议
5g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)300.26
FormulaC16H12O6
CAS No.520-34-3
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 60 mg/mL (199.8 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)

Chemical Name: 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one

InChi Key: MBNGWHIJMBWFHU-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H12O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-7,17-19H,1H3

SMILES Code: O=C1C=C(C2=CC=C(OC)C(O)=C2)OC3=CC(O)=CC(O)=C13

SynonymsLuteolin 4-methyl ether; HSDB-8101; Diosmetin; HSDB 8101; HSDB 8101; Luteolin 4'-methyl ether
实验参考方法
In Vitro

In vitro activity: Diosmetin inhibits 3H-dopamine uptake in neuroblastoma cells, as well as in small-cell lung carcinoma cells, which is be responsible for the increased vascular tone observed in vivo after treatment with Diosmetin. Moreover, Diosmetin also removes iron from iron-loaded hepatocytes revealed a good relationship between this iron-chelating ability and the cytoprotective effect. Other studies proves that Diosmetin is a cytochrome P450 inhibitor, thus inhibiting carcinogen activation and and causing pharmacokinetic interactions with co-administered drugs metabolized.

Cell Assay: In MCF-7 cells, at 24 h after the incubation of diosmetin, CYP1A1 mRNA was increased in a dose-dependent manner. In MCF-7 cells, diosmetin at 2.5 μM modestly increased CYP1A1 enzyme activity, with an activity increase in cells, while diosmetin at 5 μM did not increase the enzyme activity compared to controls in cells. Compared with controls, diosmetin dose-dependently increased the capacity of nuclear extracts to bind an oligonucleotide containing the AhR-binding sequence of CYP1A1.

In VivoPretreatment with diosmetin significantly reduces serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-κB activation in cerulein-induced acute pancreatitis.
Animal modelMice: Experimental acute pancreatitis is induced in mice by seven intraperitoneal injection of cerulein (50 μg/kg) at hourly intervals. Diosmetin (100 mg/kg) or vehicle is pretreated 2 h before the first cerulein injection. After 6 h, 9 h, 12 h of the first cerulein injection, the severity of acute pancreatitis is evaluated biochemically and morphologically
Formulation & Dosage100 mg/kg
References

Pharmacol Res. 1992 Dec;26(4):395-402; Cancer Res. 1998 Jul 1;58(13):2754-60.